Artificial intelligence (AI) software developer MaxQ AI has signed a distribution agreement with AI software provider EnvoyAI, a subsidiary of advanced visualization (AV) technology firm TeraRecon.
Under the deal, MaxQ AI's Accipio intracranial hemorrhage (ICH) platform will be available on the EnvoyAI Exchange marketplace in the U.S. and European Union. Furthermore, the company's Accipio Ix ICH identification and triaging software will be sold through EnvoyAI and TeraRecon's PACS distribution channels, as well as to TeraRecon's current installed base, according to the companies.
Accipio Ix has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the CE Mark.
